Clinical Trial Search

Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants

Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants

Primary: GVHD-free Survival — 60; 69; 59; 47 participants

Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects

Primary: Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure — 41 Participants

Primary: Number of Participants With Complete Response (CR) — 34 Participants

Primary: Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years — 38; 48 percentage of participants

Primary: Number of Patients Who Achieve CR or PR by Day 28 of Treatment — 62 Participants

Primary: Incidence of Acute GVHD — 45.0 percentage of participants

Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants

Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63

Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08

Primary: The Number of Patients With GVHD/Relapse-free (GRFS) Survival — 25 Participants

Primary: The Cumulative Incidence of Grade II-IV Acute GVHD up to Day 100 After Stem Cell Infusion — 32 Percentage of participants

Primary: Grades II-IV aGVHD — 11 Participants

Primary: GVHD-free Survival Rate — 33.3 percentage of patients

Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants

Primary: Determining Whether the Hepatic Adverse Event-free (NCI Grades II-IV) Survival at Day 42 After an HLA-matched Transplant for Hematologic Malignancy Can be Improved by…

Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants

Primary: Number of High Risk Patients Who Develop Steroid Refractory GVHD — 6 Participants

Primary: Corticosteroid-Requiring Chronic Graft-Versus-Host Disease (cGVHD) Rate — 13.3; 35.2 percentage of participants — p=0.0008

Primary: Number of Subjects Not Experiencing Grade II-IV Acute Graph Versus Host Disease (aGVHD) — 3; 18; 0 Participants

Primary: Distribution of Acute GVHD Grades (MAGIC Criteria) at Time of PET/CT Scan — 0; 2; 0; 0 Participants

Primary: Cummalative Incidence of Grade 2 to 4 Acute Graft vs Host Diesease (GVHD) at Day 100 Post Transplant in HSCT Recipients — 3.3 percentage of participants — p=<0.05

Primary: Chronic Graft-vs-Host Disease (cGvHD) — 20 percentage of participants

Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373

Primary: Phase I: Maximum Tolerated Dose (MTD) in Milligrams — 5 MTD of oral LBH589 in milligrams

Primary: Number of Patients With Grades II-IV Acute GVHD — 39; 22; 3 Participants

Primary: Grade II-IV Acute GVHD — 30 percentage of participants

Primary: Maximum Tolerated Dose of High-dose Cyclophosphamide as Determined by Number of Participants Who Tolerated Each Dose of Cyclophosphamide — 4; 4; 2 Participants